Ionis Pharmaceuticals today revealed that it has finalized enrollment in its pivotal trial evaluating zilganersen (ION373), an investigational RNA-targeted therapy aimed at treating children and adults with Alexander disease (AxD), a rare, progressive, and ultimately fatal neurological disorder. The trial’s…
Bristol Myers Squibb today announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who…
Bristol Myers Squibb today announced the validation of its near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi) as part of a mid-year update on its environmental initiatives. This milestone underscores the company’s progress in reducing emissions…
Revolution Medicines, a clinical-stage oncology company dedicated to targeting RAS-addicted cancers, has announced the publication of a peer-reviewed research paper in Cancer Discovery. The paper showcases the efficacy of their RAS(ON) multi-selective inhibitor, RMC-7977 (representative of investigational drug RMC-6236), in…
Today, AbbVie announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a new indication for upadacitinib (RINVOQ®; 15 mg, once daily) to treat adult patients with giant cell…
Daiichi Sankyo (TSE: 4568) has inaugurated a new affiliate dedicated to its oncology business in Athens, Greece, underscoring its commitment to addressing the needs of cancer patients in Europe. Thomais Konstantopoulou has been appointed as the Country Manager for Daiichi…
Lebrikizumab has been approved for treating moderate-to-severe atopic dermatitis in adolescents (12 years and older) and adults who require systemic therapy. This treatment received approval from the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in…
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash. APEIRON holds royalty rights to QARZIBA® (dinutuximab beta), a treatment for high-risk neuroblastoma. In addition to the initial payment, Ligand…
AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU) for patients with primary advanced or recurrent endometrial cancer. The combination of Imfinzi plus chemotherapy as a first-line treatment followed by Lynparza and Imfinzi…
AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under the accelerated assessment procedure by the European Medicines Agency (EMA) for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. Sipavibart is an investigational long-acting antibody designed to provide…
AbbVie announced today that Robert A. Michael has taken on the role of Chief Executive Officer (CEO) and joined the company’s Board of Directors, effective immediately. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has been the CEO…
MSD, known as Merck outside the United States and Canada, will host its second-quarter 2024 sales and earnings conference call for institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 30. During the call, company executives will provide…